Debt to Equity Ratio: A measure of a company's financial leverage calculated by dividing its long-term debt by shareholders equity. Calculated as: Total Debt / Shareholders Equity
NeuroSense Therapeutics Ltd. (NRSN) Debt to Equity Ratio data is not available for the most recently reported fiscal year, ending 2024-12-31.
| Income Statement Financials | |
-- |
|
$-10.21M |
|
-- |
|
-- |
|
$9.90M |
|
$-9.90M |
|
$-0.31M |
|
$-10.21M |
|
$-10.21M |
|
$-10.21M |
|
$-10.21M |
|
$-10.21M |
|
$-10.21M |
|
$-9.90M |
|
$-9.88M |
|
18.60M |
|
18.60M |
|
$-0.54 |
|
$-0.54 |
|
| Balance Sheet Financials | |
$4.40M |
|
$0.07M |
|
$0.17M |
|
$4.58M |
|
$1.99M |
|
-- |
|
-- |
|
$1.99M |
|
$2.58M |
|
$2.58M |
|
$2.58M |
|
23.23M |
|
| Cash Flow Statement Financials | |
$-10.13M |
|
$0.00M |
|
$10.91M |
|
$2.64M |
|
$3.38M |
|
$0.74M |
|
$0.56M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
2.21 |
|
-- |
|
-- |
|
-- |
|
|
Debt to Equity Ratio |
-- |
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-10.14M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-395.28% |
|
-395.28% |
|
-223.17% |
|
-395.28% |
|
$0.11 |
|
$-0.55 |
|
$-0.54 |
|